c103696.htm - Prepared by Imprima

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

November 2, 2010

________________

 

        NOVO NORDISK A/S       
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 


 

 

logo.gif

Company Announcement

1 November 2010

Novo Nordisk A/S – Share repurchase programme

On 27 October 2010 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 1.4 billion in the period from 27 October 2010 to 23 December 2010.

Since the announcement as of 27 October 2010, the following transactions have been made under the programme:

 

 

Number of

Average

Transaction value,

 

shares

purchase price

DKK

Accumulated, last

 

 

 

announcement

0

 

0

27 October 2010

77,000

545.5462

42,007,057

28 October 2010

43,000

555.1200

23,870,160

29 October 2010

55,000

562.1122

30,916,171

Accumulated under

 

 

 

the programme

175,000

 

96,793,388

 

 

 

 

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 99,000 B shares in the period from 27 October 2010 to 29 October 2010. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 26,874,755 treasury shares, corresponding to 4.5% of the share capital. The total amount of shares in the company is 600,000,000 including treasury shares.

Company Announcement no 61 / 2010

Page 1 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 


 

 

 

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 29,890 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

 

Further information:

 

 

 

Media:

Investors:

 

 

Anne Margrethe Hauge

Klaus Bülow Davidsen

Tel: (+45) 4442 3450

Tel: (+45) 4442 3176

amhg@novonordisk.com

klda@novonordisk.com

 

 

 

Kasper Roseeuw Poulsen

 

Tel: (+45) 4442 4471

 

krop@novonordisk.com

 

 

 

Jannick Lindegaard

 

Tel: (+45) 4442 4765

 

jlis@novonordisk.com

 

 

In North America:

In North America:

Lori Moore

Hans Rommer

Tel: (+1) 609 919 7991

Tel: (+1) 609 919 7937

lrmo@novonordisk.com

hrmm@novonordisk.com

 

 

 

 

Company Announcement no 61 / 2010

Page 2 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: November 2, 2010

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer